Mistletoe (Viscum album) is a semi-parasitic plant that anchors itself to host trees — most commonly apple, oak, and fir — across Europe and parts of Asia. Its berries, leaves, and stems contain a rich mix of bioactive compounds, most notably lectins and viscotoxins, which are responsible for its medicinal effects. In European integrative oncology, standardized mistletoe extracts are among the most widely used complementary cancer therapies, particularly in Germany, Switzerland, and Austria.

Mistletoe's lectins — especially Mistletoe Lectin I (ML-I) — appear to activate immune cells including natural killer cells and T-lymphocytes, helping the body's defenses stay active during and after conventional cancer treatment. These same compounds have shown the ability to trigger programmed cell death in abnormal cells and may help reduce inflammation tied to tumor growth. The overall effect in practice is less about directly attacking cancer and more about supporting resilience, reducing treatment side effects, and maintaining energy and wellbeing.

In clinical settings, mistletoe is almost exclusively given as a subcutaneous injection (under the skin, typically 3 times per week), which allows precise dosing of active compounds. This route is not self-administered at home — it requires guidance from a trained integrative or naturopathic physician. Oral capsules and liquid extracts are available for general wellness use but deliver far less of the active lectins and have a much weaker evidence base. Raw mistletoe plant material — especially the berries — is poisonous and should never be consumed directly.

• Cancer-related fatigue
• Quality of life during cancer treatment
• Immune support during chemotherapy
• High blood pressure
• Anxiety and depression related to illness
• Tumor-related pain management (adjunctive)
• Side effects of radiation therapy
• General immune weakness

• Cancer recurrence risk reduction (emerging evidence — observational data suggests possible benefit in breast and colorectal cancer; confirmatory RCT data still developing)
• Infection during immunosuppression (some evidence of reduced serious infections in chemotherapy patients using mistletoe)

Mistletoe is not found in any food — it is a semi-parasitic plant whose active compounds (lectins, viscotoxins) are unique to the plant and not present in the diet. To support the same goals as mistletoe therapy — immune resilience, inflammation control, and energy during illness — focus on: (1) Shiitake and maitake mushrooms, which contain beta-glucans that activate natural killer cells similarly to mistletoe lectins; (2) Cruciferous vegetables (broccoli, Brussels sprouts, kale) for their sulforaphane content, which supports immune surveillance and cancer-protective pathways; (3) Berries (blueberries, blackberries) rich in anthocyanins that reduce oxidative stress and inflammation; (4) Green tea, which contains EGCG — a polyphenol with immune-modulating and anti-tumor properties; (5) Garlic and onions, which contain allicin and quercetin to support immune cell activity. Foods to avoid during mistletoe therapy: heavy alcohol intake (may blunt immune response) and high-sugar processed foods (promote inflammation and immune suppression).

Orally, European mistletoe seems to be well tolerated when used in small amounts

• Recommended daily: Injectable extract (clinical use): 1–30 mg subcutaneously 2–3 times per week, titrated by a trained practitioner based on immune response and tolerance. The most commonly used preparations (Iscador, Helixor) are dosed in standardized lectin units and must be guided by an integrative physician or oncologist. Oral capsules/extracts: typically 300–600 mg of standardized extract daily for general immune support — though oral evidence is far weaker.
• Best time of day: Injectable forms are typically given in the morning or early afternoon. Evening dosing is sometimes preferred when flu-like side effects occur, so any discomfort happens during sleep.
• With or without food: Oral forms are generally better tolerated with food to reduce stomach upset. Injections are independent of meals.
• Time to effect: Immune marker changes and injection site responses typically appear within 2–4 weeks. Quality-of-life and fatigue benefits in cancer care are usually reported by 4–8 weeks of consistent use.
• How long to take it: In integrative oncology, mistletoe is often used continuously throughout and after cancer treatment — sometimes for years — under physician supervision. For general immune support, many practitioners recommend seasonal or 3-month cycles with reassessment. Never use long-term without a qualified practitioner overseeing your care.